Table 1 Dose-response subgroup analysis of the risk of hypertension and type 2 diabetes with parathyroid hormone

Country

 USA

6

1.07(1.04, 1.10)

65.4

0.013

4

1.03(1.00, 1.06)

0

0.465

 Netherlands

1

1.01(0.99,1.03)

-

-

-

-

-

-

 Korean

1

1.01(0.98, 1.04)

-

-

1

0.99(0.97, 1.01)

-

-

Detection method

electrochemiluminescence immunoassay

3

1.06(1.02, 1.10)

39.9

0.189

2

1.05(0.99, 1.10)

44.9

0.178

chemiluminescence assay

4

1.03(1.00, 1.06)

81.2

0.001

3

1.00(0.98, 1.02)

0

0.558

immunoradiometric assay

1

1.05(1.02, 1.08)

-

-

-

-

-

-

Sample size

 > 3000

4

1.04(1.01, 1.06)

72.3

0.013

4

1.03(1.00, 1.06)

0

0.465

 ≤3000

4

1.10(1.02, 1.19)

86.3

0

1

0.99(0.97, 1.01)

-

-

Follow-up

 > 3

4

1.04(1.01, 1.07)

74.4

0.008

1

1.08(1.01, 1.15)

-

-

 ≤3

1

1.08(1.04, 1.12)

-

-

1

1.02(0.97, 1.07)

-

-

Sex

 M/W

7

1.05(1.02, 1.07)

80.2

0

-

-

-

-

 M

1

1.22(1.04, 1.42)

-

-

-

-

-

-

Design

 cohort

5

1.05(1.02, 1.08)

79.1

0.001

2

1.04(1.00, 1.08)

42.8

0.186

 cross-sectional

3

1.07(1.00, 1.15)

86.8

0.001

3

0.99(0.97, 1.01)

0

0.882

Hypertension definition

 measured

7

1.05(1.02, 1.07)

80.2

0

-

-

-

-

 self-reported

1

1.22(1.04, 1.42)

-

-

-

-

-

-

Definition

 diabetes

-

-

-

-

3

1.03(1.00, 1.07)

3.7

0.354

 hyperglycaemia

-

-

-

-

2

0.99(0.97, 1.01)

0

0.831